Measurable residual disease-driven therapy after radiotherapy for early-stage follicular lymphoma
Mené en Italie sur 106 adultes atteints d'un lymphome folliculaire (durée médiane : 46,1 mois ; 53 % de femmes), cet essai multicentrique de phase II évalue l'efficacité, du point de vue du taux de maladie résiduelle mesurable, d'une radiothérapie
In The Lancet Haematology, Alessandro Pulsoni and colleagues1 present the results of the MIRO study, a single arm, multicentre, phase 2 trial examining the use of BCL2::IGH, detected by PCR, as a biomarker to guide consolidative systemic therapy after definitive radiotherapy for patients with early-stage follicular lymphoma. Measurable residual disease (MRD)-guided treatment consolidation has shown promise for follicular lymphoma treated with systemic therapy, although has mainly been investigated in patients with advanced disease.2,3 This intriguing study by Pulsoni and colleagues1 provides valuable information to aid in answering perhaps the most pertinent question in the treatment of early-stage follicular lymphoma: what, if anything, should be added to radiotherapy to improve survival outcomes?